H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Context Therapeutics (CNTX – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $1.15.
According to TipRanks, Bodnar is an analyst with an average return of -13.8% and a 28.89% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Imunon, Ventyx Biosciences, and Context Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Context Therapeutics with a $6.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.87 and a one-year low of $0.95. Currently, Context Therapeutics has an average volume of 268.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Read More on CNTX:
